Contributions
Abstract: EP561
Type: E-Poster Presentation
Session title: Aggressive Non-Hodgkin lymphoma - Clinical
Background
GFR is an independent prognostic factor for survival in some types of cancer, but its effect on outcome of patients with B-LCL has not been systematically analyzed.
Aims
To analyze the effect of GFR on outcome of patients with B-LCL, independently and in relation to IPI factors, bulk and treatment.
Methods
We analyzed overall survival (OS) and progression-free survival (PFS) of newly diagnosed patients with B-LCL treated at our institution between 2012 and 2019 and correlated these outcomes to the international prognostic index (IPI), bulky disease at diagnosis, treatment and GFR, calculated according to the CKD-EPI equation. Patients were excluded from the study if they had previous chronic kidney disease or obstructive nephropathy at diagnosis.
Results
We identified 288 patients fulfilling entry criteria, 151 (52%) male and 137 (48%) female. Median age was 58 and range 18-87. 136 patients were treated with R-CHOP21, 82 with R-CHOEP14 (patients younger than 60 with aaIPI 2-3), 38 with DA-R-EPOCH (fit patients older than 60 with aaIPI 2-3 since 2016) and 32 with R-miniCHOP or R-CEOP (unfit or patients with significant cardiac comorbidities). Responding patients with bulky or extranodal disease or in partial remission were irradiated after end of systemic treatment.
Age (p<0.001), IPI (p<0.001), treatment (p=0.02) and GFR (p=0.01) were statistically significantly associated with overall survival in univariate analysis. Only age (p=0.013) and GFR (p=0.004) remained significant in multivariate analysis. The effect of GFR was similar in all subgroups irrespective of treatment or IPI. Adding GFR to IPI resulted in 3 groups of patients with significantly different prognosis.
Conclusion
GFR is a significant prognostic factor in patients with B-LCL independent of IPI, bulk or treatment. The combination of GFR with IPI might result in better prognostic stratification of patients than IPI alone.
Keyword(s): Diffuse large B cell lymphoma, Prognosis
Abstract: EP561
Type: E-Poster Presentation
Session title: Aggressive Non-Hodgkin lymphoma - Clinical
Background
GFR is an independent prognostic factor for survival in some types of cancer, but its effect on outcome of patients with B-LCL has not been systematically analyzed.
Aims
To analyze the effect of GFR on outcome of patients with B-LCL, independently and in relation to IPI factors, bulk and treatment.
Methods
We analyzed overall survival (OS) and progression-free survival (PFS) of newly diagnosed patients with B-LCL treated at our institution between 2012 and 2019 and correlated these outcomes to the international prognostic index (IPI), bulky disease at diagnosis, treatment and GFR, calculated according to the CKD-EPI equation. Patients were excluded from the study if they had previous chronic kidney disease or obstructive nephropathy at diagnosis.
Results
We identified 288 patients fulfilling entry criteria, 151 (52%) male and 137 (48%) female. Median age was 58 and range 18-87. 136 patients were treated with R-CHOP21, 82 with R-CHOEP14 (patients younger than 60 with aaIPI 2-3), 38 with DA-R-EPOCH (fit patients older than 60 with aaIPI 2-3 since 2016) and 32 with R-miniCHOP or R-CEOP (unfit or patients with significant cardiac comorbidities). Responding patients with bulky or extranodal disease or in partial remission were irradiated after end of systemic treatment.
Age (p<0.001), IPI (p<0.001), treatment (p=0.02) and GFR (p=0.01) were statistically significantly associated with overall survival in univariate analysis. Only age (p=0.013) and GFR (p=0.004) remained significant in multivariate analysis. The effect of GFR was similar in all subgroups irrespective of treatment or IPI. Adding GFR to IPI resulted in 3 groups of patients with significantly different prognosis.
Conclusion
GFR is a significant prognostic factor in patients with B-LCL independent of IPI, bulk or treatment. The combination of GFR with IPI might result in better prognostic stratification of patients than IPI alone.
Keyword(s): Diffuse large B cell lymphoma, Prognosis